CAR-T cell manufacturing: Major process parameters and next-generation strategies-Reference-Cited by-全球学者库

CAR-T cell manufacturing: Major process parameters and next-generation strategies

Published:2024-01-16 Issue:2 Volume:221 Page:
ISSN:0022-1007
Container-title:Journal of Experimental Medicine
language:en
Short-container-title:

Author:

Ayala Ceja Melanie¹^ORCID,Khericha Mobina¹^ORCID,Harris Caitlin M.¹^ORCID,Puig-Saus Cristina²³⁴^ORCID,Chen Yvonne Y.¹³⁴⁵^ORCID

Affiliation:

1. University of California−Los Angeles 1 Department of Microbiology, Immunology, and Molecular Genetics, , Los Angeles, CA, USA

2. University of California−Los Angeles 2 Department of Medicine, , Los Angeles, CA, USA

3. Jonsson Comprehensive Cancer Center, University of California−Los Angeles 3 , Los Angeles, CA, USA

4. Parker Institute for Cancer Immunotherapy Center at University of California−Los Angeles 4 , Los Angeles, CA, USA

5. University of California−Los Angeles 5 Department of Chemical and Biomolecular Engineering, , Los Angeles, CA, USA

Abstract

Chimeric antigen receptor (CAR)-T cell therapies have demonstrated strong curative potential and become a critical component in the array of B-cell malignancy treatments. Successful deployment of CAR-T cell therapies to treat hematologic and solid cancers, as well as other indications such as autoimmune diseases, is dependent on effective CAR-T cell manufacturing that impacts not only product safety and efficacy but also overall accessibility to patients in need. In this review, we discuss the major process parameters of autologous CAR-T cell manufacturing, as well as regulatory considerations and ongoing developments that will enable the next generation of CAR-T cell therapies.

Funder

California Institute for Regenerative Medicine

Parker Institute for Cancer Immunotherapy

Jean and Stephen Kaplan

Publisher

Rockefeller University Press

Subject

Immunology,Immunology and Allergy

Link

https://rupress.org/jem/article-pdf/doi/10.1084/jem.20230903/1922823/jem_20230903.pdf

Reference156 articles.

1. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study;Abramson;Lancet,2020

2. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: Primary analysis of the phase 3 TRANSFORM study;Abramson;Blood,2023

3. In vivo generation of CAR T cells selectively in human CD4+ lymphocytes;Agarwal;Mol. Ther.,2020

4. Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy;Al Hadidi;Bone Marrow Transpl.,2023

5. Functionality and cell senescence of CD4/CD8-selected CD20 CAR T cells manufactured using the automated CliniMACS Prodigy® platform;Aleksandrova;Transfus. Med. Hemother.,2019